REN and chronic kidney disease: The two largest trials that explored the clinical benefit of finerenone on the renal and cardiovascular outcomes in patients with mild to severe CKD and type 2 DM, on top of the maximum tolerated renin–angiotensin system inhibition, were the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) [17] and the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trials [18].